By Fineline Cube 
US-based Kymera Therapeutics Inc. (NASDAQ: KYMR) announced updates to its IRAK4-targeted program collaboration with Sanofi. Under the revised agreement, KT-485/SAR447971, an IRAK4-targeting degrader discovered by Kymera, has been selected by Sanofi for clinical development. Phase I trials are anticipated to commence next year. Kymera received a $20 million milestone payment in Q2 2025 for preclinical progress. Future milestones could reach up to $975 million, along with double-digit royalties and a 50/50 US profit-sharing option.
Collaboration Background
Kymera initially partnered with Sanofi in July 2020. The original deal included a $150 million upfront payment and potential payments exceeding $2 billion. The initial focus was on the co-development of KT-474 as a potential follow-on to Dupixent (dupilumab).
Strategic Shift
Following Sanofi’s prioritization of KT-485, the development of KT-474 will be discontinued. This decision reflects Sanofi’s commitment to advancing the most promising candidates in its pipeline.-Fineline Info & Tech